UK Approves Novo Nordisk’s Weight-Loss Drug for Wider Use
Britain’s medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), approved Novo Nordisk’s semaglutide-based weight-loss treatment for broader use in adults with obesity, according to a statement released on June 11. The decision expands access to the drug, which has been available under specific conditions since 2021, following a review of its safety and efficacy, the MHRA said.
How Does the Drug Work?
Semaglutide, marketed as Wegovy for weight loss, is a GLP-1 receptor agonist that mimics a hormone involved in regulating appetite and food intake. It is administered via weekly injections and has been shown to help patients achieve significant weight reduction when combined with diet and exercise, according to clinical trials published in *The New England Journal of Medicine*.
Regulatory Process and Safety
The MHRA’s approval followed a review of data from over 5,000 participants in randomized controlled trials, which demonstrated that semaglutide led to an average weight loss of 15% over 68 weeks, compared to 2.6% with a placebo. The agency emphasized that the drug should be prescribed by healthcare professionals and monitored for potential side effects, including gastrointestinal issues and a rare risk of thyroid tumors observed in animal studies.
Impact on Public Health
The decision comes as obesity rates in the UK continue to rise, with over 28% of adults classified as obese, according to Public Health England. Health experts have noted that semaglutide could play a critical role in addressing the condition, but caution that it is not a standalone solution. “This drug is a tool, not a magic bullet,” said Dr. Sarah Jarvis, a UK-based physician and medical broadcaster. “Lifestyle changes remain essential.”
Comparison With Other Treatments
Semaglutide joins a growing list of weight-loss medications, including tirzepatide (Mounjaro) and phentermine-topiramate (Qsymia). Unlike some alternatives, semaglutide’s mechanism targets both appetite and metabolism, offering a dual approach. However, its higher cost—approximately £1,500 per year in the UK—raises concerns about accessibility, according to the National Institute for Health and Care Excellence (NICE).
What’s Next for Patients?
The MHRA’s expanded approval means the drug is now available through the NHS for eligible patients, though eligibility criteria remain strict. Patients must have a body mass index (BMI) of 30 or higher or a BMI of 27.5 with weight-related health issues, and they must have tried other weight-management strategies without success.
FAQ: Key Questions About the Approval
Q: How effective is semaglutide for weight loss?
A: Clinical trials show an average weight loss of 15% over 68 weeks, though individual results vary.
Q: Are there any long-term risks?
A: The MHRA notes ongoing monitoring is required due to potential risks, including thyroid C-cell tumors in animal studies.
Q: How much does the drug cost?
A: The annual cost is approximately £1,500, though NHS funding may reduce out-of-pocket expenses for eligible patients.
Why This Matters
The approval reflects a shift in addressing obesity as a chronic condition rather than a lifestyle choice. Similar decisions in the US and EU have sparked debates about balancing access to innovative treatments with cost controls. As the UK’s healthcare system grapples with rising obesity rates, the expanded use of semaglutide could set a precedent for future treatments.
Source Citations
– Medicines and Healthcare products Regulatory Agency (MHRA): [www.mhra.gov.uk](https://www.mhra.gov.uk)
– *The New England Journal of Medicine*: [www.nejm.org](https://www.nejm.org)
– National Institute for Health and Care Excellence (NICE): [www.nice.org.uk](https://www.nice.org.uk)